IL290798B2 - Tyrosine kinase inhibitor drug candidates for cancer treatment - Google Patents
Tyrosine kinase inhibitor drug candidates for cancer treatmentInfo
- Publication number
- IL290798B2 IL290798B2 IL290798A IL29079822A IL290798B2 IL 290798 B2 IL290798 B2 IL 290798B2 IL 290798 A IL290798 A IL 290798A IL 29079822 A IL29079822 A IL 29079822A IL 290798 B2 IL290798 B2 IL 290798B2
- Authority
- IL
- Israel
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- cancer treatment
- drug candidates
- inhibitor drug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910817505.XA CN112442009B (en) | 2019-08-30 | 2019-08-30 | Deuterated compounds and their use for treating cancer |
| CN201910818779.0A CN112442011B (en) | 2019-08-30 | 2019-08-30 | A prodrug compound and its application in treating cancer |
| CN201910818675.XA CN112442010B (en) | 2019-08-30 | 2019-08-30 | A class of prodrug compounds and their application in treating cancer |
| US202062994364P | 2020-03-25 | 2020-03-25 | |
| PCT/CA2020/051177 WO2021035360A1 (en) | 2019-08-30 | 2020-08-28 | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL290798A IL290798A (en) | 2022-04-01 |
| IL290798B1 IL290798B1 (en) | 2026-02-01 |
| IL290798B2 true IL290798B2 (en) | 2026-06-01 |
Family
ID=74684795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290798A IL290798B2 (en) | 2019-08-30 | 2020-08-28 | Tyrosine kinase inhibitor drug candidates for cancer treatment |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4021912A4 (en) |
| AU (1) | AU2020338490B2 (en) |
| CA (1) | CA3147801A1 (en) |
| IL (1) | IL290798B2 (en) |
| WO (1) | WO2021035360A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3232086A1 (en) * | 2021-10-15 | 2023-04-20 | Peter Jarrett | Prodrugs of axitinib |
| US20260049071A1 (en) * | 2022-08-08 | 2026-02-19 | Beyang Therapeutics Co., Ltd. | Protein tyrosine kinase inhibitor and medical use thereof |
| CN120329323B (en) * | 2025-04-16 | 2026-01-13 | 黄冈鲁班药业股份有限公司 | A method for preparing cefepime side chains and their applications |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002369A2 (en) * | 1999-07-02 | 2001-01-11 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| CN106336397A (en) * | 2015-07-07 | 2017-01-18 | 郭明山 | Novel compound for treating ophthalmic diseases |
| CN106478596A (en) * | 2015-08-25 | 2017-03-08 | 李建成 | A kind of noval chemical compound as treatment ophthalmic diseasess |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106317017A (en) | 2015-07-10 | 2017-01-11 | 李建成 | Novel compound used for treating ophthalmic diseases |
| CN110372598A (en) * | 2018-04-13 | 2019-10-25 | 成都海创药业有限公司 | A kind of new method synthesizing deuterated amide and deuterated sulfonamide |
-
2020
- 2020-08-28 WO PCT/CA2020/051177 patent/WO2021035360A1/en not_active Ceased
- 2020-08-28 CA CA3147801A patent/CA3147801A1/en active Pending
- 2020-08-28 IL IL290798A patent/IL290798B2/en unknown
- 2020-08-28 AU AU2020338490A patent/AU2020338490B2/en active Active
- 2020-08-28 EP EP20857153.9A patent/EP4021912A4/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002369A2 (en) * | 1999-07-02 | 2001-01-11 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| CN106336397A (en) * | 2015-07-07 | 2017-01-18 | 郭明山 | Novel compound for treating ophthalmic diseases |
| CN106478596A (en) * | 2015-08-25 | 2017-03-08 | 李建成 | A kind of noval chemical compound as treatment ophthalmic diseasess |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021035360A1 (en) | 2021-03-04 |
| AU2020338490B2 (en) | 2025-09-18 |
| EP4021912A4 (en) | 2023-08-23 |
| IL290798A (en) | 2022-04-01 |
| CA3147801A1 (en) | 2021-03-04 |
| EP4021912A1 (en) | 2022-07-06 |
| AU2020338490A1 (en) | 2022-03-17 |
| IL290798B1 (en) | 2026-02-01 |